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The results of phase 3 efficacy trials have shown that acellular and whole-cell pertussis vaccines can confer
protection against whooping cough. However, despite the advances in vaccine development, clinical trials have
not provided significant new information on the mechanism of protective immunity against Bordetella pertussis.
Classical approaches based on measurement of antibody responses to individual antigens failed to define an
immunological correlate of protection. A reliable animal model, predictive of acellular and whole-cell pertussis
vaccine potency in children, would facilitate an elucidation of the mechanism of immune protection against
B. pertussis and would assist in the regulatory control and future development of pertussis vaccines. In this
study, we have shown that the rate of B. pertussis clearance following respiratory challenge of immunized mice
correlated with vaccine efficacy in children. Using this model together with mice with targeted disruptions of
the gamma interferon (IFN-g) receptor, interleukin-4 or immunoglobulin heavy-chain genes, we have demon-
strated an absolute requirement for B cells or their products in bacterial clearance and a role for IFN-g in
immunity generated by previous infection or immunization with the whole-cell pertussis vaccine. The results
of passive immunization experiments suggested that protection early after immunization with acellular per-
tussis vaccines is mediated by antibody against multiple protective antigens. In contrast, more complete
protection conferred by previous infection or immunization with whole-cell pertussis vaccines reflected the
induction of Th1 cells. Our findings suggest that the mechanism of immunity against B. pertussis involves
humoral and cellular immune responses which are not directed against a single protective antigen and thus
provide an explanation for previous failures to define an immunological correlate of protection.
Recent clinical trials have demonstrated that acellular per-
tussis vaccines (Pa) comprising different combinations of the
putative protective antigens, pertussis toxin (PT), filamentous
hemagglutinin (FHA), pertactin (PRN), and fimbriae from
Bordetella pertussis, can confer protection against World
Health Organization-defined whooping cough (1, 6, 11, 12, 37,
39). The safety profile of Pa from the clinical trials revealed a
considerable reduction in the number of mild or severe adverse
events in vaccinated children compared with conventional
whole-cell vaccines (Pw) (6, 11, 12, 21, 37, 39). However, the
mechanism of protection conferred by natural or vaccine-in-
duced immunity remains to be defined. Assessment of anti-
body responses in the clinical trials did not reveal a clear
correlation between serum antibody responses against a single
B. pertussis antigen and protection (10–12, 21, 37). Investiga-
tions of cell-mediated immunity against B. pertussis in children
demonstrated that recovery from whooping cough or immuni-
zation with Pw is associated with selective induction of Th1
cells (30), whereas immunization with Pa induces T cells with
a mixed Th1-Th2 cytokine profile (2, 31, 32). These studies
suggest that distinct arms of the immune response may make
different contributions to protection induced by different types
of immunization or natural infection.
Animal models for infectious diseases of humans have made
significant contributions to our understanding of the immuno-
logical mechanisms that determine resolution of infection or
progression to disease and provide the most realistic possibility
of defining the mechanism of immune protection against
B. pertussis. Although the murine intracerebral challenge
model has been used to assess the potency of Pw (14, 20), this
test fails to predict the efficacy of Pa in humans. In contrast,
aerosol inoculation results in a respiratory infection in adult
mice displaying many of the characteristics seen in infected
children and has been used by a number of laboratories to
examine mechanisms of immunity to B. pertussis (18, 19, 22, 26,
33, 34, 36).
Studies in our laboratory using the murine respiratory infec-
tion model have provided evidence that T cells may play a
significant role in protection against B. pertussis (3, 18, 19, 22,
28). We have demonstrated that adoptive transfer of CD41 T
cells from convalescent mice can confer protection against
B. pertussis respiratory challenge in irradiated or T-cell-defi-
cient athymic mice (22). Respiratory infection or immunization
with Pw selectively primed Th1 cells, whereas immunization
with Pa induced high antibody levels and Th2 cells (3, 28).
Furthermore, addition of interleukin (IL-12) to an acellular
vaccine polarized the T-cell response to the Th1 subtype and
improved its protective efficacy (18). These studies point to a
role for Th1 cells in protection against B. pertussis but do not
exclude a role for antibody.
In the present study, the availability of samples of the Pw
and Pa vaccines that had been tested in the National Institute
of Allergy and Infectious Diseases-sponsored phase 3 clinical
* Corresponding author. Mailing address: Infection and Immunity
Group, Department of Biology, National University of Ireland, May-
nooth, Co. Kildare, Ireland. Phone: 353-1-7083838. Fax: 353-1-7083845.
E-mail: kmills@may.ie.
594
trials in Italy (11) and Sweden (12) allowed us to demonstrate
that protection in the murine respiratory challenge model cor-
relates with vaccine efficacy in children. It also allowed us to
compare these results with those obtained with Pw and Pa that
were tested in the Senegal efficacy trial (37). We have used this
model in the context of active and passive immunization of
normal mice and mice with disruptions in genes encoding ei-
ther the membrane axon of the m-chain constant region of the
immunoglobulin (Ig) molecule (Ig2/2), IL-4 (IL-42/2), or the
gamma interferon (IFN-g) receptor (IFN-gR2/2) to examine
the mechanisms of natural and vaccine-induced immunity
against B. pertussis. Taken together with the results of our
previous studies (3, 18, 19, 22, 28), the findings demonstrate
complementary roles for cellular and humoral immunity in
protection against B. pertussis.
MATERIALS AND METHODS
Mice. All mice used were commercially obtained (B&K Universal Ltd., Hull,
United Kingdom) and were bred and maintained according to the guidelines of
the Irish Department of Health. The IFN-gR2/2 mice, in which IFN-g is non-
functional (13), were used with the kind permission of M. Aguet (Molecular
Biology Department, University of Zurich, Zurich, Switzerland). These mice
were generated from the wild-type 129Sv/Ev (H-2b) strain. The IL-42/2 mice
(16) were used with the kind permission of Werner Muller (Institute for Genet-
ics, University of Cologne, Cologne, Germany), and the Ig2/2 (mMT) mice (15)
were used with the kind permission of Klaus Rajewsky (Institute for Genetics,
University of Cologne). The Ig2/2 and IL-42/2 mice were generated from
wild-type C57BL/6 (H-2b) mice. Unless otherwise stated, all mice were 8 to 12
weeks old at the initiation of experiments.
Bacterial antigens. Heat-killed B. pertussis was prepared by incubation of cells
at 80°C for 30 min. Genetically detoxified recombinant PT (rPT) mutant (PT-
9K/129G) (27) and native FHA and PRN prepared from B. pertussis were kindly
provided by Rino Rappuoli (Chiron SpA, Siena, Italy).
Immunization. Groups of 20 BALB/c mice were immunized intraperitoneally
at 0 and 4 weeks with 0.2 human dose of either Wellcome (W), Pasteur Me´rieux
(PM), or U.S. Connaught Laboratories Inc. (CLI) Pw, SmithKline Beecham (SB)
Pa2, SB Pa3, PM Pa2, Canadian Connaught Laboratories Ltd. (CLL) Pa5, and
Chiron Biocine (CB) Pa3. The antigenic compositions of the vaccines and their
estimated efficacies in children are shown in Table 1. With the exception of the
W Pw, which was the third British Reference Preparation (88/522) from the
National Institute for Biological Standards and Control, Potters Bar, Hertford-
shire, United Kingdom, all vaccines were provided by the manufacturers as
combined diphtheria-tetanus-pertussis formulations adsorbed to alum. Mice
were challenged 2 weeks after the second immunization. In experiments com-
paring active and passive immunization and assessing the contribution of indi-
vidual antigens to protection, BALB/c mice were immunized with W Pw (0.2
human dose) or 5.0 mg each of different combinations of Pa components (rPT,
FHA, and PRN). In active immunization experiments, mice were challenged 2
weeks after two immunizations (0 and 4 weeks). In passive immunization exper-
iments, mice were immunized three times (0, 3, and 6 weeks) and were bled at
week 8. Recipient BALB/c mice were injected intravenously with 0.1 ml serum
from mice immunized with W Pw or Pa (rPT, FHA, and PRN) or with 0.1 ml of
each serum (in different combinations) from mice immunized with rPT, FHA, or
PRN alone. Mice were challenged 4 h after passive transfer of antibody.
B. pertussis respiratory challenge model. Respiratory infection of mice was
initiated by aerosol challenge by a modification of the method described by Sato
et al. (33). B. pertussis W28 phase I was grown under agitation conditions at 37°C
in Stainer-Scholte liquid medium. Bacteria from a 48-h culture were resuspended
at a concentration of approximately 2 3 1010 CFU/ml in physiological saline
containing 1% casein. The challenge inoculum was administered to mice as an
aerosol over a period of 15 min by means of a nebulizer as described previously
(18). Groups of four mice were sacrificed at various times after aerosol challenge
to assess the number of viable B. pertussis in the lungs. Lungs were removed
aseptically from infected mice and homogenized in 1 ml of sterile physiological
saline with 1% casein on ice. Aliquots of 100 ml of undiluted homogenate or of
serially diluted homogenate from individual lungs were spotted in triplicate onto
Bordet-Gengou agar plates, and the number of CFU was estimated after 5 days
of incubation at 37°C. Results are reported as the mean viable B. pertussis for
individual lungs from at least four mice per time point per experimental group.
The limit of detection was approximately log10 0.5 CFU per lung.
Anti-B. pertussis antibodies. The levels of B. pertussis-specific antibodies in
serum and lung lavage (22) were determined by enzyme-linked immunosorbent
assay using purified B. pertussis antigens (2 mg/ml) to coat plates. Bound anti-
bodies were detected using alkaline phosphatase-conjugated anti-mouse IgG or
IgG subclasses (PharMingen, San Diego, Calif.).
Cytokine assays. Spleen cells (2 3 106/ml) from naive and immune mice were
cultured with heat-killed B. pertussis (105, 106, or 107/ml), heat-inactivated PT
(0.2 to 5.0 mg/ml), FHA (0.2 to 5.0 mg/ml), PRN (0.2 to 5.0 mg/ml), or medium
alone. Supernatants were removed after 72 h, and IFN-g and IL-5 concentrations
were determined by immunoassay as previously described (18). Results are given
as mean cytokine concentrations against the optimum antigen concentration for
groups of four mice tested individually in triplicate.
Statistical analysis. Calculation of the areas under bacterial clearance curves
and the regression analysis were performed by using the Fig. P graphics and
statistical software.
RESULTS
Protection in a murine respiratory challenge model corre-
lates with vaccine efficacy in children. We have evaluated three
Pw and five Pa, including clinical lots evaluated in different
efficacy trials (Table 1). The number of bacteria in naive con-
trol mice increased to a peak 7 to 10 days after challenge and
gradually declined to undetectable levels after 35 to 42 days
(Fig. 1). Immunization with the W Pw or PM Pw, which like
other European Pw have estimated efficacy in the region of
95% (6, 8, 25, 37), conferred the highest level of protection in
mice, with complete bacterial clearance 5 to 7 days after chal-
lenge. In contrast, CLI Pw, which protected only 36 and 48%
of children against whooping cough in the National Institute of
Allergy and Infectious Diseases-sponsored Italian and Swedish
trials, respectively (11, 12), showed significantly poorer clear-
ance in immunized mice, with significant levels of bacteria still
detectable in the lungs 10 days after challenge. Mice immu-
nized with different Pa showed an early decline in the bacterial
load in the lungs by day 3 after challenge but failed to com-
pletely eliminate the bacteria until 11 to 14 days later. The rate
of bacterial clearance was lower in mice immunized with SB
Pa2 than in those immunized with the SB Pa3. The same lots
of vaccine had 59 and 84% efficacy, respectively, in the Swedish
and Italian trials (11, 12). In contrast, another two-component
vaccine manufactured by Pasteur Me´rieux (PM Pa2) generated
an equivalent level of protection as the CLL Pa5 in the mouse
model. The estimated absolute efficacy of these vaccines was
85% in the Senegal (37) and Swedish (12) trials. Finally, the
clinical lot of the CB Pa3, which protected 84% of children in
the Italian trial (11), conferred a high level of protection in the
mouse model. The numbers of CFU in lungs were close to or
below the level of detection 3, 7, 10, and 14 days after chal-
lenge. The almost identical clearance curves observed in mice
with a recent clinical lot of the CB Pa3 provides convincing
evidence of the reproducibility of the test within experiments
and is indicative of the long-term stability of this vaccine (Fig.
TABLE 1. Vaccine composition and estimated efficacy in children
Vaccine Antigencompositiona (mg) Trial/study
b
Estimated
efficacy
(%)
CLI Pw Whole cell Italy/Sweden 36/48
PM Pw Whole cell Senegal 96
W Pw Whole cell United Kingdomc 93–94
SB Pa2 PTd (25), FHA (25) Sweden 59
SB Pa3 PTd (25), FHA (25), PRN (8) Italy 84
CLL Pa5 PTd (10), FHA (5), PRN (3),
Fim2,3 (5)
Sweden 85
PM Pa2 PTd (25), FHA (25) Senegal 85
CB Pa3 rPT (5), FHA (2.5), PRN (2.5) Italy 84
a Antigens included chemically detoxified PT (PTd), genetically detoxified
(rPT), FHA, PRN, and fimbriae of types 2 and 3 (Fim2,3).
b The vaccines were assessed in the efficacy trials in Stockholm (1992 to 1995),
Sweden (12); Italy (11); and Senegal (37).
c The estimated efficacy quoted for the Wellcome Pw has been reported from
epidemiological studies in the United Kingdom (8, 25) and concur with the high
level of efficacy of the Wellcome/Medeva Pw tested in the efficacy trial in
Stockholm (1993 to 1996), Sweden (1).
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1). Further evidence of the reproducibility of the aerosol chal-
lenge model was evident from comparisons of the vaccines
from the same manufacturer tested on different occasions
(data not shown).
We performed statistical analysis to test the significance of
the correlation between protection in children and in the mu-
rine respiratory model. Regression analysis revealed a highly
significant (P , 0.001) correlation between the bacterial clear-
ance in mice and the estimated efficacy in children (Fig. 2).
Expression of the area under the clearance curves (days 0 to 14
after challenge) of immunized mice as a ratio of the area under
the curve for unimmunized control mice allows compensation
for any experiment-to-experiment variation in the challenge,
and this ratio gave a negative correlation (r 5 20.941) with the
estimated vaccine efficacy in children (Fig. 2). It should be
noted that the data on efficacy in children are derived from a
number of trials and studies carried out under different con-
ditions.
Gene knockout mice reveal distinct mechanisms of natural
and vaccine-induced immunity. To examine the roles of B cells
and of two key type 1 and type 2 cytokines, IFN-g and IL-4, in
natural and vaccine-induced immunity against B. pertussis, we
examined the course of infection in Ig2/2, IL-42/2, IFN-
gR2/2, and wild-type mice that had previously been infected or
immunized with Pw or Pa. Since Ig2/2 mice develop a chronic
infection after primary challenge (19), we could not examine
the role of B cells in a secondary infection. Nevertheless, al-
though IFN-gR2/2 mice developed an atypical disseminated
infection, they did clear the bacteria from the lungs 80 to 100
days after challenge (19). However, following reinfection, the
FIG. 1. Kinetics of B. pertussis clearance from the lungs after respiratory challenge of mice immunized with Pw or Pa. Groups of 20 BALB/c mice were immunized
intraperitoneally at 0 and 4 weeks with 0.2 human dose of either W Pw, PM Pw, CLI Pw, SB Pa2, SB Pa3, PM Pa2, CLL Pa5, or CB Pa3 (a, lot used in Italian trial
manufactured in 1992; b, clinical lot manufactured in 1996) or with alum alone (control). Two weeks after the second immunization, mice were challenged with
B. pertussis W28 and CFU counts were performed on individual lung homogenate at intervals after challenge. Results are mean (6standard error) viable B. pertussis
counts from four mice per group at each time point.
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rate of bacterial clearance was lower in IFN-gR2/2 mice than
in the wild-type strain (Fig. 3). Bacteria were undetectable in
the lungs of wild-type 129Sv/Ev mice 7 days after challenge,
whereas the CFU counts in the lungs of IFN-gR2/2 mice
declined to low levels on day 7 but rebounded on day 10 and
were still at detectable levels 14 days after challenge. In con-
trast, the rate of bacterial clearance was higher in IL-42/2 mice
than in the wild-type C57BL/6 mice (Fig. 3).
Immunization of Ig2/2 mice with pertussis vaccines did not
confer protection against infection with B. pertussis; the levels
of bacteria in the lung remained at high levels 7 and 14 days
after respiratory challenge (Fig. 3). In contrast, the levels of
bacteria were low or undetectable 7 to 14 days after challenge
of wild-type mice following two immunizations with Pw (Fig.
3). However, the numbers of viable bacteria were higher 7 and
10 days after challenge in IFN-gR2/2 mice than in 129Sv/Ev
mice but were almost identical in IL-42/2 and the wild-type
C57BL/6 mice immunized with Pw (Fig. 3). Disruption of the
IL-4 or IFN-gR gene had little effect on clearance of B. per-
tussis from the lungs of mice immunized with Pa (Fig. 3).
Immune responses in normal and gene knockout mice. An
examination of the systemic T-cell responses in infected and
immunized mice revealed that the earliest bacterial clearance
was observed in mice with the most polarized Th1 responses.
Respiratory infection or immunization with Pw selectively
stimulated systemic Th1 cells specific for PT, FHA, and PRN
in all strains examined except the IFN-gR2/2 mice, where IL-5
was detected in addition to IFN-g and IL-2 (Fig. 4 and data not
shown). In contrast, immunization with Pa induced T cells that
secreted high levels of IL-5 in BALB/c and 129Sv/Ev mice and
lower levels in C57BL/6 mice but almost undetectable levels of
IFN-g in all strains except the IL-42/2 mice (Fig. 4). B-cell-
deficient mice were found to have defective T-cell responses.
In comparison with the wild-type C57BL/6 mice, B. pertussis-
specific T-cell proliferation and cytokine production were sig-
nificantly reduced in Ig2/2 mice following infection or immu-
FIG. 2. Correlation between bacterial clearance from the lungs following
aerosol challenge of immunized mice and vaccine efficacy in children. The areas
under the curves of bacterial clearance 0 to 14 days after challenge of mice
immunized with a vaccine, expressed as a ratio of area under the curves for
control unimmunized mice in the same experiment (as shown in Fig. 1, except
area was calculated up to 14 days in all cases), were plotted against the estimated
efficacy of the vaccine shown in Table 1. The efficacies of the CLI Pw and W Pw
were taken as the means of the values given in Table 1.
FIG. 3. Bacterial clearance following B. pertussis respiratory challenge of immunized or convalescent gene-disrupted mice. IL-42/2 (A) and IFN-gR2/2 (B) and the
wild-type C57BL/6 and 129Sv/Ev mice were infected with B. pertussis, allowed to clear the bacteria (12 to 14 weeks), and challenged 2 weeks later. Ig2/2, IL-42/2 (C
and E), and IFN-gR2/2 (D and F) mice and the wild-type C57BL/6 and 129Sv/Ev mice were immunized twice (weeks 0 and 4) with the W Pw (C and D) or Pa prepared
from rPT, FHA, and PRN adsorbed to alum (E and F) and were challenged 2 weeks after the second immunization. Results from four experiments are mean
(6standard error) CFU per lung for four to nine mice per time point.
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nization with Pw, and responses were almost undetectable
following immunization with Pa (Fig. 4 and data not shown).
Apart from the B-cell-deficient mice, which failed to mount
an antibody response, immunization with Pa generated high
antibody titers against PT and PRN and modest responses
against FHA, whereas Pw induced high antibody titers against
PRN and modest levels against PT and FHA (Table 2 and data
not shown). Although the IgG antibody response to individual
antigens were lower following infection, significant levels of
antibodies against whole bacteria were detected (not shown).
We failed to find a significant correlation between IgG titers
against individual antigens and protection against B. pertussis
challenge.
Analysis of the subclass of the anti-B. pertussis IgG response
suggested that protection was associated with IgG2a antibody
responses. The responses were highly polarized to IgG2a in
infected wild-type mice and to a lesser extent in mice immu-
nized with Pw (Fig. 5). In contrast, IgG1 was the dominant
subclass in mice immunized with the Pa. Deletion of functional
IFN-gR2/2 resulted in an increase in the ratio of IgG2a to
IgG1, whereas deletion of IL-4 had the opposite effect (Fig. 5).
Passive transfer of antibodies confers protection against
B. pertussis. Since we had demonstrated defective T-cell re-
sponses in Ig2/2 mice and since these mice do not make ma-
ture B cells, we could not conclude that their failure to confer
resistance against B. pertussis challenge following immuniza-
tion was solely due to defective antibody production. We had
previously demonstrated that antibody from convalescent mice
had only a marginal effect on the rate of bacterial clearance
when passively transferred prior to challenge (22). Here we
show that antibody may play a more significant role in protec-
tion induced by immunization, especially with Pa. Passive
transfer of serum from BALB/c mice immunized with Pw or Pa
resulted in a 3- to 5-log reduction in the bacterial load early
after challenge (Fig. 6). However, compared with active im-
munization with Pw, where bacteria are undetectable on day 7,
passive immunization with anti-Pw serum was associated with
a rebound in the counts on day 14 and a delay in complete
bacterial elimination until day 21 (Fig. 6). In contrast, active
and passive immunization with Pa resulted in similar kinetics
of bacterial clearance after challenge. Transfer of serum (0.1
ml) from animals that had received three immunizations with
the Pw or Pa resulted in serum antibody titers against PT,
FHA, and PRN at the time of challenge similar to those ob-
served in mice that received two active immunizations with the
same vaccines (Table 2 and data not shown). Analysis of bron-
choalveolar lavage samples from recipient mice at the time of
challenge demonstrated that significant levels of B. pertussis-
specific IgG had transudated into the lung (Table 2).
TABLE 2. Anti-PT IgG levels in serum and lungs
at time of challenge
Immunizationa
Antibody titerb (mean 6 SE)
Serum Lungs
Pw active 1,600 6 20 NTc
Pw passive 1,587 6 50 40 6 20
Pa active 12,800 6 410 NT
Pa passive 10,413 6 1,400 320 6 50
a Mice were immunized as described in the legend to Fig. 6, and serum and
lung lavage samples were recovered from groups of four mice 2 weeks after
active immunization or 4 h after passive immunization.
b Mean reciprocal endpoint titer (based on 1.0 ml of lavage fluid for lungs) for
four mice in each experimental group.
c NT, not tested.
FIG. 4. T-cell responses in immune wild-type and gene-disrupted mice. BALB/c (B/c), 129Sv/Ev (129), IFN-gR2/2, C57BL/6 (C57BL), IL-42/2, or Ig2/2 mice were
immunized or infected as described in the legend to Fig. 3, and responses were assessed on the day of challenge. Spleen cells were stimulated in vitro with killed
B. pertussis, inactivated PT, FHA, or PRN, and supernatants were assessed for IL-5 and IFN-g by immunoassay. Results are mean responses for four mice assessed
individually in triplicate.
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Multiple antigen protective mechanism. Since the exact con-
tribution of distinct B. pertussis antigens to protection has not
been established, we used the murine model to examine the
protective effect of active or passive immunization with indi-
vidual antigens and antigen combinations found in a number of
Pa. Two active immunizations (two doses at 4-week intervals)
with rPT resulted in an almost 5-log drop in the bacterial
counts 7 days after challenge (Fig. 7). Immunization with PRN
also had a significant protective effect, whereas FHA alone was
the least protective of the three antigens tested. However, the
combination of FHA and PT was more protective than PT
alone, and the addition of PRN resulted in a further modest
enhancement of the rate of bacterial clearance in immunized
mice.
Passive transfer of serum from mice immunized with PT
alone resulted in an approximately 4-log reduction of the CFU
counts in the lungs compared with serum from naive mice (Fig.
7). Anti-PRN antibodies also conferred a high level of protec-
tion, but anti-FHA antibodies alone only had only a modest
effect on the rate of bacterial clearance. However, the addition
of anti-FHA antibodies enhanced the protective effect of anti-
PT, whereas the addition of anti-PRN serum to this combina-
tion had no further protective effect.
DISCUSSION
The murine intracerebral challenge test (14) has been used
to assess the potency of Pw, but until now there has been no
animal model in which protection correlates with Pa efficacy in
children. In this study, we provide evidence that a murine
model of respiratory challenge with live B. pertussis may fulfill
this role. Although certain of the features of the human dis-
ease, notably the persistent coughing and neurological mani-
festations, are not evident in the murine model, the course of
respiratory infection has many of the characteristics of that
seen in infants (7, 26, 33). Furthermore, we have preliminary
evidence that the systemic effects of B. pertussis infection in
mice include elevated levels of proinflammatory cytokines in
the brain (17). The highly significant correlation between bac-
terial clearance in immunized mice and vaccine efficacy in
children suggests that the murine respiratory challenge model
will have considerable applications in the regulatory control
and future development of pertussis vaccines. Our data for the
mouse model are consistent with the failure to identify a single
immunological correlate of protection in clinical trials and
suggest that immunogenicity studies against individual B. per-
tussis antigens in mice are unlikely to predict vaccine efficacy in
children. In contrast, assessment of the lung bacterial clear-
ance following aerosol challenge of immunized mice, relative
to naive mice or to mice immunized with a standard vaccine
preparation, may provide a reproducible and more definitive
method of evaluating pertussis vaccines prior to licensure.
The murine respiratory challenge model has also provided
an experimental basis for an elucidation of the mechanisms of
natural and vaccine-induced immunity against B. pertussis. We
have previously demonstrated that B. pertussis-infected IFN-
gR2/2 mice develop atypical disseminating disease, whereas
both Ig2/2 and athymic mice develop a chronic infection fol-
lowing challenge with B. pertussis (19, 22). In the present study,
we observed a delayed clearance of bacteria from the lungs of
IFN-gR2/2 mice primed by previous infection or immuniza-
tion with Pw and enhanced clearance following rechallenge of
IL-42/2 mice. These observations may be explained on the
basis of defective and enhanced Th1 responses through re-
moval of positive and negative regulators of Th1 cells, respec-
tively. The rebound effect observed on day 10 postchallenge in
IFN-gR2/2 mice previously infected or immunized with Pw,
and to a lesser extent in conventional mice immunized with Pa,
may reflect lack of effective cell-mediated immunity against
intracellular B. pertussis. The early decline in bacterial counts
may be mediated through the effector function of antibody,
whereas complete clearance may be dependent on IFN-g-me-
diated activation of macrophages and neutrophils (38). In con-
ventional mice, priming by infection or immunization with Pw
induced the most polarized Th1 response and conferred the
FIG. 5. Anti-PT IgG subclasses in immune wild-type and gene-disrupted
mice. Mice were immunized or infected as described in the legends to Fig. 3 and
4, and antibody responses were tested by enzyme-linked immunosorbent assay on
the day of challenge. Results are reciprocal endpoint titers.
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highest level of protection. This finding is consistent with the
observation in children of selective induction of Th1 cells fol-
lowing infection (30) or immunization with Pw (32) and with
our previous studies in mice that Th1 cells can clear the infec-
tion after adoptive transfer into irradiated recipients (22). The
outcome of challenge of IFN-gR2/2 and IL-42/2 mice immu-
nized with Pa and Pw also suggests a degree of redundancy in
the cytokines involved in vaccine-induced immunity against
B. pertussis. Although there was some evidence of broadening
of the Th1 and Th2 responses and the profile of IgG subclasses
induced with Pa in IFN-gR2/2 and IL-42/2 mice and with Pw
in IL-42/2 mice, the rate of bacterial clearance was not signif-
icantly different in knockout compared with wild-type strains.
It appears that either Th1 or Th2 cytokines may provide helper
function for antibody production but that Th1 cytokines may
play an additional role, perhaps mediating direct cellular im-
munity against intracellular B. pertussis (4, 19, 35, 38) in the
lungs.
The demonstration that protection against B. pertussis can
be conferred by passive transfer of anti-B. pertussis serum and
the failure to prime protective immune responses in Ig2/2
mice are in agreement with previous suggestions that antibod-
ies can make a major contribution to vaccine-induced protec-
tion against B. pertussis (7, 23, 29, 34, 36, 40). Although we have
previously reported that passive transfer of convalescent serum
has little protective effect against respiratory infection in mice,
the present study demonstrated that targeted disruption of the
Ig m-chain gene did compromise the capacity of the immune
system to clear the infection, suggesting that antibody may also
be involved in natural immunity. However, as these mice do
not have mature B cells, the defect may not be confined to
antibody production. Indeed, we observed weak or undetect-
able antigen-specific T-cell responses in Ig2/2 mice primed by
infection or immunization with Pw or Pa. This finding is con-
sistent with some, but not all, studies that have reported de-
fective T-cell priming in Ig2/2 mice and suggests a role for B
cells in antigen presentation (9, 19, 24). Furthermore, the ob-
servation that active immunization of mice with Pw leads to
complete bacterial clearance as early as 5 days after challenge,
whereas immunization with Pa or passive transfer of anti-Pw
serum was associated with a delay in bacterial elimination and
occasional rebound in bacterial load, suggests that direct cell-
mediated immunity is also required for optimum protection
conferred by immunization. It is also noteworthy that in our
studies animals were challenged at the peak of the antibody
response, and it has been reported that antibody levels decline
rapidly after immunization in children, especially with Pa (5).
In contrast, studies from clinical trials and from the mouse
FIG. 6. Clearance of B. pertussis following active or passive immunization with Pw or Pa. (A) Active immunization. BALB/c mice were immunized twice (0 and 4
weeks) with W Pw or Pa (rPT, FHA, and PRN). (B) Passive immunization. Serum was prepared from BALB/c mice immunized three times (0, 3, and 6 weeks) with
Pa or Pw, and recipient mice were injected with 0.1 ml 4 h before respiratory challenge. Results are mean (6standard error) CFU per lung for four mice per time point.
FIG. 7. Multiple protective antigens of B. pertussis. (A) Active immunization. Mice were immunized twice (0 and 4 weeks) with 5 mg of either FHA, PRN, rPT, rPT
and FHA, or rPT, FHA, and PRN adsorbed to alum or with alum only (control) and were challenged 2 weeks later. (B) Passive immunization. Sera were recovered
from mice 2 weeks after three immunizations (0, 3, and 6 weeks) with rPT, FHA, or PRN only and 0.1 ml of each antiserum, in the combinations described for active
immunization, injected (intravenously) into naive BALB/c mice, which were challenged 4 h later. Results are mean (6standard error) CFU per lung for four mice per
time point.
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model have demonstrated that T-cell responses are maintained
for more prolonged periods after immunization (3, 5), empha-
sizing the requirement for both arms of the adaptive immune
response in vaccine induced protection.
The contribution of different B. pertussis antigens to protec-
tion has been extensively debated (7, 23, 29, 34, 36). The results
of active and passive immunization experiments in our study
demonstrate that either PT or PRN can confer relatively high
levels of protection. Although FHA alone was comparatively
less protective, it did augment the protective efficacy of PT. In
addition, we have preliminary evidence that fimbriae augment
the protective efficacy of PT and that PT-FHA-fimbria types 2
and 3 and PT-FHA-fimbria types 2 and 3-PRN are highly
protective combinations in the murine respiratory challenge
model (unpublished observations). These findings are consis-
tent with the results of clinical trials that have demonstrated
that five-, three-, and most two-component vaccines have
higher estimated efficacious than a monocomponent chemi-
cally detoxified PT (PTd) vaccine, albeit in different clinical
trials, with different antigen doses and inactivation procedures,
and that vaccine efficacy may increase with increasing number
of antigens in the formulation (1, 6, 11, 12, 37, 39). The poorer
protection induced by SB Pa2 compared with SB Pa3 in clinical
trials and in our mouse model suggests that PRN does make a
significant contribution to the protection afforded by these
vaccines. However, the results with other two-component vac-
cines (6, 37) suggest that, in addition to the combination of
components, the formulation of the antigens may affect the
potency of Pa. We cannot exclude the contribution of other
antigens, including adenylate cyclase or heat shock proteins, to
protection. Indeed, the superior efficacy of Pw may reflect a
contribution of additional antigens or bacterial components
that contribute to adjuvanticity, such as lipopolysaccharide,
which is known to contribute to pertussis vaccine efficacy by
enhancing Th1 responses through IL-12 production (18).
Our findings also provide an explanation for the failure to
find an immunological correlate of protection induced by per-
tussis vaccines in children. Clinical trials have until recently
focused exclusively on humoral immunity and have shown that
monospecific antibody responses against either FHA, PT,
PRN, or fimbriae do not correlate with protection (10–12, 21,
37). However, the results of our study demonstrate that B. per-
tussis has multiple protective antigens and antibody and T-cell
responses against several antigens may have an additive effect
for optimum protection. Antibody appears to be important in
limiting infection and disease by preventing initial bacterial
adherence to ciliated epithelial cells in the respiratory tract
(40), through the neutralization of bacterial toxins, and may
also be required for the removal of bacteria through opsoniza-
tion. Our data suggested that early bacterial clearance was
associated with high levels of complement-fixing IgG2a anti-
bodies, which were influenced by the levels of functional IFN-g
induced by immunization. Although the induction of T cells
with mixed Th1-Th2 cytokine profiles appear to mediate the
same level of protection as Th1 cells, a polarized Th2 response
was associated with a delay in complete bacterial clearance
from the lungs. It is now accepted that B. pertussis can occupy
an intracellular niche in the lungs, and we and others have
demonstrated that IFN-g is required to contain infection to the
respiratory mucosae by abolishing a reservoir of B. pertussis
within macrophages (4, 19, 35, 38). Therefore, the mechanisms
that prevent replication and dissemination and eventually suc-
ceed in eliminating B. pertussis from the body appear to reflect
the dual extra- and intracellular location of the bacteria in the
host and require the distinct but coordinated functions of the
cellular and humoral arms of the immune response for optimal
protection.
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